Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder of unknown etiology, initially described in 1835. It is characterized by keratotic follicular papules, well-demarcated salmon-colored erythematous scaly plaques interspersed with distinct islands of uninvolved skin, and palmoplantar keratoderma. Is PRP a systemic disease? Skin is mainly affected in PRP. Despite its clinical heterogeneity, PRP could be associated with a variety of rheumatologic, infectious, neoplastic, and other extracutaneous manifestations. We accept the hypothesis of not only an association but also a causative relation between skin and systemic manifestations with possible common underlying pathomechanisms such as systemic immunologic processes and superantigen mimicry.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clindermatol.2019.07.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case of pityriasis rubra pilaris secondary to ponatinib.
SAGE Open Med Case Rep
January 2025
Departement of Dermatology, Charles-Le Moyne Hospital, Longueuil, QC, Canada.
Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose reduction and recurred more mildly at a lower dose.
View Article and Find Full Text PDFCytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status.
J Cutan Pathol
December 2024
Department of Dermatology and Pathology, University of California, California, USA.
Background: Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T-cell lymphoma. Most of these are typified by Type 2 (e.
View Article and Find Full Text PDFOff-label dermatologic uses of IL-23 inhibitors.
J Dermatolog Treat
December 2024
Department of Dermatology, University of Illinois College of Medicine, Chicago, IL, USA.
Background: While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.
Methods: We conducted searches on PubMed and for clinical trials, observational studies, case series, and case reports assessing use of the three IL-23 inhibitors for non-psoriatic dermatologic conditions.
Atypical adult type pityriasis rubra pilaris.
Indian J Dermatol Venereol Leprol
November 2024
Department of Dermatology, Venereology & Leprosy, Gujarat Medical Education and Research Society Medical College & Hospital, Gandhinagar, India.
Grover's disease-like patterns in early pityriasis rubra pilaris.
J Dtsch Dermatol Ges
November 2024
Department of Dermatology, University of Heidelberg, Heidelberg, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!